百家乐怎么玩-澳门百家乐官网娱乐城网址_网上百家乐是不是真的_全讯网888 (中国)·官方网站

Recent advances in the synthesis, stability, and activation of platinum(IV) anticancer prodrugs
elsevier

Published on Coordination Chemistry Reviews (1 September 2021)

 

Author(s): Zoufeng Xu,Zhigang Wang, Zhiqin Deng, Guangyu Zhu*

 

Abstract

Platinum-based anticancer drugs have been widely applied in clinical settings for more than 40 years. The remarkable breakthroughs that have come from the use of these complexes in cancer therapy have stimulated a continual search for new platinum anticancer drugs. The most promising result of these efforts is a prodrug strategy based on the use of platinum(IV) versions of the traditional platinum(II) anticancer drugs. Hence, the design of synthetic methods for platinum(IV) prodrugs and an understanding of their hydrolytic stability and intracellular activation processes are critical for the development of platinum(IV) prodrugs for cancer therapy. In this review, we summarize recent progress in this field from a comprehensive viewpoint, with an emphasis first on the oxidation processes in chemical environments where platinum(II) compounds are converted to their platinum(IV) species, followed by the reduction processes in biological environments where platinum(IV) species are converted back to platinum(II) forms. First, recent approaches that use new oxidizing reagents to synthesize platinum(IV) prodrugs are summarized, and the oxidation mechanisms and outer-sphere functionalization of platinum(IV) prodrugs are examined. Second, the hydrolysis of platinum(IV) complexes, which has sometimes been underexplored, is discussed, and the factors associated with the hydrolytic stability of platinum(IV) complexes are reviewed. Last, we focus on the reduction of platinum(IV) prodrugs, from the perspectives of reduction potential, rate of reduction, reducing agents, and reduction products. The need for new strategies to achieve controllable intracellular reduction of platinum(IV) prodrugs is emphasized. This review aims to help researchers to improve their understanding of platinum(IV) anticancer prodrugs and hopefully to generate new ideas, strategies, and applications in the area of metal-based drugs.
 

20210901

Read more: https://www.sciencedirect.com/science/article/pii/S0010854521002654?via%3Dihub

 

 
 
 
 
 
 
 
 
3U百家乐官网娱乐城| 456棋牌官网| 百家乐官网攻略投注法| 澳门百家乐必赢技巧| 516棋牌游戏中心 官方版| 广宗县| 世界杯赌球| 破解百家乐官网真人游戏| 百家乐筹码方形| 乐中百家乐的玩法技巧和规则| 香港六合彩官方网| 信誉百家乐官网博彩网| 太阳城百家乐怎么出千| zaixian百家乐| 百家乐怎打能赢| 申城棋牌官网| 筹码币百家乐官网麻将| 摩纳哥百家乐娱乐城| 百家乐网上真钱赌场娱乐网规则| 红安县| 百家乐押注最多是多少| 太阳城百家乐官网的破解| LV百家乐官网客户端LV| 博王娱乐| 百家乐开户送彩金28| 打百家乐官网庄闲的技巧| 真人百家乐官网作假视频| 百家乐官网必胜法hk| 大发888 casino exe| 百家乐官网娱乐平台官网网| 百家乐技巧开户网址| 百家乐官网赌博租| 百胜滩| 菲律宾百家乐排行| 赌球者| 百家乐官网任你博娱乐网| 大发888真人新浪微群| 百家乐官网庄多还是闲多| 太阳城sun866| 真人百家乐轮盘| 百家乐官网系列抢庄龙|